Memory Disorders Clinical Trials

Active, recruiting:

Sponsor: Genentech (Lauriet Study)
Intervention: RO7105705 (Monoclonal antibody binding to tau)
Indication: Moderate AD
Clinicaltrials.gov identifier: NCT03828747
PI: Sharon Sha, MD
Contact: Jenn Gaudioso, 650-206-0963, jenn.gaudioso@stanford.edu
Inclusion criteria:
·       MMSE 16-21 (inclusive)
·       CDR (global) 1 or 2
·       Age 50-85
·       Stable AD meds for > 2 months

Active, not recruiting:

Sponsor: Biogen (Tango Study)
Intervention: BIIB092 (Monoclonal antibody binding to tau)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT03352557
PI: Sharon Sha, MD
Contact: Nischal Acharya, 650-460-9573, acharya5@stanford.edu

Sponsor: Genentech (Tauriel Study)
Intervention: RO7105705 (Monoclonal antibody binding to tau)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT03289143
PI: Sharon Sha, MD
Contact: Jenn Gaudioso, 650-206-0963, jenn.gaudioso@stanford.edu

Upcoming:

Sponsor: Alzheimer's Disease Cooperative Study (PeaceAD Study)
Intervention: Prazosin
Indication: Probable or possible AD and disruptive agitation
Clinicaltrials.gov identifier: NCT03710642
PI: Victor Henderson, MD and Sharon Sha, MD
Contacts: Amanda Ng, (650)485-9560, amandang@stanford.edu

Completing, not recruiting:

Sponsor: Novartis (Generations II Study)
Intervention: CNP520 (Active BACE-1 Inhibitor)
Target Population: Cognitively Unimpaired APOE₄ Homozygotes or Amyloid Positive Heterozygotes
Clinicaltrials.gov identifier: NCT03131453
PI: Sharon Sha, MD
Contacts: Amanda Ng, (650)485-9560, amandang@stanford.edu

Sponsor: Novartis (Generations I Study)
Intervention: CAD106 (Induces Active Antibody without activating Aβ-reactive T cells) and CNP520 (BACE-1 Inhibitor)
Target Population: Cognitively Unimpaired APOE₄ Homozygotes
Clinicaltrials.gov identifier: NCT02565511
PI: Sharon Sha, MD
Contacts: Hanna Balcha, (650)223-9662, hannafb@stanford.edu

Sponsor: Eisai (MissionAD Study)
Intervention: Elenbecestat (BACE 1 inhibitor)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT02956486
PI: Sharon Sha, MD
Contacts: Hanna Balcha, (650)223-9662, hannafb@stanford.edu

Sponsor: Biogen (Emerge Study)
Intervention: BIIB037 (Monoclonal antibody)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT02484547
PI: Sharon Sha, MD
Contact: Jenn Gaudioso, 650-206-0963, jenn.gaudioso@stanford.edu

Sponsor: Genentech (Cread Study)
Intervention: Crenezumab (Monoclonal antibody)
Indication: MCI/Mild AD
Clinicaltrials.gov identifier: NCT02670083
PI: Sharon Sha, MD
Contact: Jenn Gaudioso, 650-206-0963, jenn.gaudioso@stanford.edu